| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6c82f1477b71e93f1ff6e9b27d67ec77 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4433
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-14 |
| filingDate |
2016-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9cbbaa6f2ba9584928a39e9a49fc6e14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ef4636a929c9c7241819910d72277b5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67e57c1a70d3b3abc53b6510e0cad1b3 |
| publicationDate |
2017-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2017015439-A1 |
| titleOfInvention |
Crystalline form of a hepatitis c virus inhibitor |
| abstract |
The invention provides the crystalline hydrate of [(S)-2-((2S,4S)-2-{4-[5'-chloro-4'-({6-[(R)-4-(2,2-dimethyl-propionyl)-2-methyl-piperazin-1-yl]-pyridine-3-carbonyl}-amino)-2'-trifluoromethoxy-biphenyl-4-yl]-1H-imidazol-2-yl}-4-methoxy-pyrrolidin-1-yl)-2-oxo-1-(tetrahydro-pyran-4-yl)-ethyl]-carbamic acid methyl ester dihydrochloride The invention also provides pharmaceutical compositions comprising thecrystalline form, methods of using the crystalline form to treat hepatitis C virus infection, and processes useful for preparing the crystalline form. |
| priorityDate |
2015-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |